These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31483158)

  • 1. Generic atorvastatin and rosuvastatin in the South Korean market: time of introduction in relation to manufacturer characteristics.
    Son KB
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):541-548. PubMed ID: 31483158
    [No Abstract]   [Full Text] [Related]  

  • 2. Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate.
    Park J; Bae S; Lee TJ; Son KB
    Front Pharmacol; 2020; 11():232. PubMed ID: 32210817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications.
    Kwon HY; Godman B
    BMC Health Serv Res; 2016 Apr; 16():130. PubMed ID: 27080530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa.
    de Jager H; Suleman F
    Int J Clin Pharm; 2019 Feb; 41(1):81-87. PubMed ID: 30478491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Who initiates price competition when generic entrants are introduced into the South Korean pharmaceutical market?
    Son KB
    Front Public Health; 2022; 10():934161. PubMed ID: 36187703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
    Simoens S; Sinnaeve PR
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):49-60. PubMed ID: 23242669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.
    Godman B; Bishop I; Campbell SM; Malmström RE; Truter I
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):323-30. PubMed ID: 25338546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is greater generic competition also linked to lower drug prices in South Korea?
    Son KB
    Health Econ Rev; 2020 Sep; 10(1):30. PubMed ID: 32930889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?
    Son KB
    Front Public Health; 2023; 11():1120729. PubMed ID: 37601172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.
    Zhang W; Guh D; Sun H; Marra CA; Lynd LD; Anis AH
    Med Care; 2016 Sep; 54(9):884-90. PubMed ID: 27213540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures.
    Son KB
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jul; 22(5):815-822. PubMed ID: 33765402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of manufacturer coupon use in the statin market.
    Daugherty JB; Maciejewski ML; Farley JF
    J Manag Care Pharm; 2013; 19(9):765-72. PubMed ID: 24156645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Evolution of Supply and Demand in Markets for Generic Drugs.
    Frank RG; McGuire TG; Nason I
    Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Use and Expenditures of Brand-name Atorvastatin After Introduction of Generic Atorvastatin.
    Warraich HJ; Salami JA; Khera R; Valero-Elizondo J; Okunrintemi V; Nasir K
    JAMA Intern Med; 2018 May; 178(5):719-721. PubMed ID: 29525818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.